Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pacira Pharm Inc (NQ: PCRX ) 20.21 +0.84 (+4.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,166,493 Open 19.55 Bid (Size) 20.25 (1) Ask (Size) 20.45 (1) Prev. Close 19.37 Today's Range 19.52 - 20.35 52wk Range 19.34 - 40.16 Shares Outstanding 44,454,792 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals. July 17, 2024 PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying. Via Chartmill Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025 July 10, 2024 From Pacira BioSciences Via GlobeNewswire Performance YTD -36.84% -36.84% 1 Month -30.43% -30.43% 3 Month -22.57% -22.57% 6 Month -37.43% -37.43% 1 Year -45.16% -45.16% More News Read More Top 5 Health Care Stocks That May Explode In July July 08, 2024 Via Benzinga This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday July 03, 2024 Via Benzinga Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights July 02, 2024 Via Benzinga NASDAQ:PCRX: good value for what you're paying. June 26, 2024 Via Chartmill NASDAQ:PCRX, an undervalued stock with good fundamentals. June 05, 2024 Via Chartmill Analyst Ratings For Pacira BioSciences May 08, 2024 Via Benzinga Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference May 30, 2024 From Pacira BioSciences Via GlobeNewswire When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. May 15, 2024 Via Chartmill Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 May 10, 2024 From Pacira BioSciences Via GlobeNewswire A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts April 09, 2024 Via Benzinga Navigating 4 Analyst Ratings For Pacira BioSciences March 01, 2024 Via Benzinga Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes May 08, 2024 From Pacira BioSciences Via GlobeNewswire PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program May 07, 2024 From Pacira BioSciences Via GlobeNewswire Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Pacira BioSciences Via GlobeNewswire Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 April 30, 2024 From Pacira BioSciences Via GlobeNewswire Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Pacira BioSciences Via GlobeNewswire Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued. March 28, 2024 Via Chartmill Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV) March 20, 2024 Via AB Newswire Topics Death Exposures Death Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee March 13, 2024 From Pacira BioSciences Via GlobeNewswire Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference March 06, 2024 From Pacira BioSciences Via GlobeNewswire When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. March 01, 2024 Via Chartmill Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results February 29, 2024 From Pacira BioSciences Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.